tiprankstipranks
Advertisement
Advertisement

HK:2696 Stock Latest News

Henlius Starts First-in-Human Trial of Novel Dual-Target Cancer ADC HLX48
Company AnnouncementsHenlius Starts First-in-Human Trial of Novel Dual-Target Cancer ADC HLX48
5d ago
2696
Henlius Doses First U.S. Patient in Global Trial of Ipilimumab Biosimilar HLX13
PremiumCompany Announcements
Henlius Doses First U.S. Patient in Global Trial of Ipilimumab Biosimilar HLX13
10d ago
2696
Henlius wins EU nod for new lung cancer use of serplulimab
PremiumCompany Announcements
Henlius wins EU nod for new lung cancer use of serplulimab
10d ago
2696
Henlius Wins GMP Green Light for HANBEIYOU Production in Mainland China
PremiumCompany Announcements
Henlius Wins GMP Green Light for HANBEIYOU Production in Mainland China
18d ago
2696
Henlius Wins NMPA Nod for First-in-Class Trispecific Prostate Cancer Therapy Trial
PremiumCompany Announcements
Henlius Wins NMPA Nod for First-in-Class Trispecific Prostate Cancer Therapy Trial
18d ago
2696
Henlius Wins Australian Nod for Phase 2 NSCLC Trial of HLX43 Combo
PremiumCompany AnnouncementsHenlius Wins Australian Nod for Phase 2 NSCLC Trial of HLX43 Combo
19d ago
2696
Henlius Phase 3 Eye Drug HLX04-O Hits Key Goals in Global wAMD Trial
Premium
Company Announcements
Henlius Phase 3 Eye Drug HLX04-O Hits Key Goals in Global wAMD Trial
19d ago
2696
Henlius Wins China Approval for New Gastric Cancer Use of HANSIZHUANG
Premium
Company Announcements
Henlius Wins China Approval for New Gastric Cancer Use of HANSIZHUANG
26d ago
2696
Henlius Starts Global Phase 1 Trial of Pembrolizumab Biosimilar HLX17 in U.S. and China
PremiumCompany Announcements
Henlius Starts Global Phase 1 Trial of Pembrolizumab Biosimilar HLX17 in U.S. and China
30d ago
2696
Henlius Wins China Approval for HANBEIYOU Breast Cancer Biosimilar
PremiumCompany Announcements
Henlius Wins China Approval for HANBEIYOU Breast Cancer Biosimilar
1M ago
2696
Henlius Starts Global Phase 2/3 Trial of ADC HLX43 in Advanced Lung Cancer
PremiumCompany Announcements
Henlius Starts Global Phase 2/3 Trial of ADC HLX43 in Advanced Lung Cancer
1M ago
2696
Henlius Starts First-Patient Dosing in Phase 1 Study of Daratumumab Biosimilar HLX15-SC for Newly Diagnosed Multiple Myeloma
PremiumCompany Announcements
Henlius Starts First-Patient Dosing in Phase 1 Study of Daratumumab Biosimilar HLX15-SC for Newly Diagnosed Multiple Myeloma
1M ago
2696
Henlius doses first patient in pivotal HLX07–serplulimab lung cancer trial in China
PremiumCompany AnnouncementsHenlius doses first patient in pivotal HLX07–serplulimab lung cancer trial in China
1M ago
2696
Henlius Wins Key EMA Backing for Serplulimab Lung Cancer Use
Premium
Company Announcements
Henlius Wins Key EMA Backing for Serplulimab Lung Cancer Use
1M ago
2696
Henlius Begins First-in-Human Trial of First-in-Class B7-H3 Cancer Fusion Protein
Premium
Company Announcements
Henlius Begins First-in-Human Trial of First-in-Class B7-H3 Cancer Fusion Protein
1M ago
2696
Henlius Wins NMPA Nod for First-in-Human Trial of Bispecific ADC HLX48
PremiumCompany Announcements
Henlius Wins NMPA Nod for First-in-Human Trial of Bispecific ADC HLX48
1M ago
2696
Henlius Wins Australian Nod to Start First-in-Class Trispecific Antibody Trial for Advanced Prostate Cancer
PremiumCompany Announcements
Henlius Wins Australian Nod to Start First-in-Class Trispecific Antibody Trial for Advanced Prostate Cancer
1M ago
2696
Henlius Doses First EU Patient in Global Phase 2 Trial of HLX43 for Advanced Lung Cancer
PremiumCompany Announcements
Henlius Doses First EU Patient in Global Phase 2 Trial of HLX43 for Advanced Lung Cancer
1M ago
2696
Henlius Shareholders Unanimously Approve 2025 Reports and Profit Distribution
PremiumCompany Announcements
Henlius Shareholders Unanimously Approve 2025 Reports and Profit Distribution
2M ago
2696
Henlius Wins Australian Nod for First-in-Class Bispecific Cancer ADC Trial
PremiumCompany AnnouncementsHenlius Wins Australian Nod for First-in-Class Bispecific Cancer ADC Trial
2M ago
2696
Henlius Starts First-in-Human Trial of Novel KAT6A/B Inhibitor HLX97 in Advanced Tumours
Premium
Company Announcements
Henlius Starts First-in-Human Trial of Novel KAT6A/B Inhibitor HLX97 in Advanced Tumours
2M ago
2696
Henlius Wins EU Approval for Two New Serplulimab Cancer Uses
Premium
Company Announcements
Henlius Wins EU Approval for Two New Serplulimab Cancer Uses
2M ago
2696

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >